Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SUNRISE-3: Bemnifosbuvir in high-risk COVID-19
NCT05629962Phase 3Completed
- Sponsor
- Atea Pharmaceuticals
- Start
- Nov 2022
- Primary completion
- Apr 2024
- Modality
- Small Molecules
- Countries
- 19
01
Overview
A Phase 3 trial of bemnifosbuvir in coronavirus disease 2019 (COVID-19), sponsored by Atea Pharmaceuticals. Started Nov 2022; status: completed.
02
Drugs
bemnifosbuvir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05629962.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05629962.